{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:46:52Z","timestamp":1787028412325,"version":"build-2736575974"},"reference-count":37,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG035355"],"award-info":[{"award-number":["R01AG035355"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG027924"],"award-info":[{"award-number":["R01AG027924"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG046205"],"award-info":[{"award-number":["R01AG046205"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01NS074969"],"award-info":[{"award-number":["P01NS074969"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50AG016574"],"award-info":[{"award-number":["P50AG016574"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Apolipoprotein E (apoE) is linked to the risk for Alzheimer\u2019s disease (AD) and thus has been suggested to be an important therapeutic target. In our drug screening effort, we identified Ondansetron (OS), an FDA-approved 5-HT3 antagonist, as an apoE-modulating drug. OS at low micromolar concentrations significantly increased apoE secretion from immortalized astrocytes and primary astrocytes derived from apoE3 and apoE4-targeted replacement mice without generating cellular toxicity. Other 5-HT3 antagonists also had similar effects as OS, though their effects were milder and required higher concentrations. Antagonists for other 5-HT receptors did not increase apoE secretion. OS also increased mRNA and protein levels of the ATB-binding cassette protein A1 (ABCA1), which is involved in lipidation and secretion of apoE. Accordingly, OS increased high molecular weight apoE. Moreover, the liver X receptor (LXR) and ABCA1 antagonists blocked the OS-induced increase of apoE secretion, indicating that the LXR-ABCA1 pathway is involved in the OS-mediated facilitation of apoE secretion from astrocytes. The effects of OS on apoE and ABCA1 were also observed in human astrocytes derived from induced pluripotent stem cells (iPSC) carrying the APOE \u03b53\/\u03b53 and APOE \u03b54\/\u03b54 genotypes. Oral administration of OS at clinically-relevant doses affected apoE levels in the liver, though the effects in the brain were not observed. Collectively, though further studies are needed to probe its effects in vivo, OS could be a potential therapeutic drug for AD by modulating poE metabolism through the LXR-ABCA1 pathway.<\/jats:p>","DOI":"10.3390\/ijms20061488","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T06:56:52Z","timestamp":1553497012000},"page":"1488","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["5-HT3 Antagonist Ondansetron Increases apoE Secretion by Modulating the LXR-ABCA1 Pathway"],"prefix":"10.3390","volume":"20","author":[{"given":"Motoko","family":"Shinohara","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA"},{"name":"Department of Aging Neurobiology, National Center for Geriatrics and Gerontology, Aichi 474-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3045-7338","authenticated-orcid":false,"given":"Mitsuru","family":"Shinohara","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA"},{"name":"Department of Aging Neurobiology, National Center for Geriatrics and Gerontology, Aichi 474-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Kanekiyo","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA"},{"name":"Neuroscience Graduate Program, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Bu","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA"},{"name":"Neuroscience Graduate Program, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,3,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrn2620","article-title":"Apolipoprotein E and its receptors in Alzheimer\u2019s disease: Pathways, pathogenesis and therapy","volume":"10","author":"Bu","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","article-title":"apoE and A\u03b2 in Alzheimer\u2019s disease: Accidental encounters or partners?","volume":"81","author":"Kanekiyo","year":"2014","journal-title":"Neuron"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11445","DOI":"10.1523\/JNEUROSCI.1972-08.2008","article-title":"Impact of apolipoprotein E (apoE) polymorphism on brain apoE levels","volume":"28","author":"Riddell","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1093\/hmg\/dds296","article-title":"Cerebrospinal fluid APOE levels: An endophenotype for genetic studies for Alzheimer\u2019s disease","volume":"21","author":"Cruchaga","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wang, C., Yu, J.T., Wang, H.F., Jiang, T., Tan, C.C., Meng, X.F., Soares, H.D., and Tan, L. (2014). Meta-analysis of peripheral blood apolipoprotein E levels in Alzheimer\u2019s disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089041"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ana.24326","article-title":"Plasma levels of apolipoprotein E and risk of dementia in the general population","volume":"77","author":"Rasmussen","year":"2015","journal-title":"Ann. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10601","DOI":"10.1073\/pnas.0701096104","article-title":"Attenuation of neuroinflammation and Alzheimer\u2019s disease pathology by liver x receptors","volume":"104","author":"Zelcer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","article-title":"apoE promotes the proteolytic degradation of A\u03b2","volume":"58","author":"Jiang","year":"2008","journal-title":"Neuron"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","article-title":"apoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models","volume":"335","author":"Cramer","year":"2012","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2147\/NDT.S61309","article-title":"The emerging role of bexarotene in the treatment of Alzheimer\u2019s disease: Current evidence","volume":"11","author":"Tousi","year":"2015","journal-title":"Neuropsychiatry Dis. Treat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrd4280","article-title":"Liver X receptors in lipid metabolism: Opportunities for drug discovery","volume":"13","author":"Hong","year":"2014","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"30538","DOI":"10.1074\/jbc.M114.600833","article-title":"Amyloid-\u03b2 pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo","volume":"289","author":"Tai","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1074\/jbc.M113.526095","article-title":"Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor\/retinoic acid receptor pathway","volume":"289","author":"Zhao","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"48702","DOI":"10.1074\/jbc.M109402200","article-title":"Dual Mechanisms of ABCA1 Regulation by Geranylgeranyl Pyrophosphate","volume":"276","author":"Gan","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.bbrc.2016.08.119","article-title":"Geranylgeranyl pyrophosphate performs as an endogenous regulator of adipocyte function via suppressing the LXR pathway","volume":"478","author":"Yeh","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/01.ATV.0000144811.94581.52","article-title":"Cyclosporin A traps ABCA1 at the plasma membrane and inhibits ABCA1-mediated lipid efflux to apolipoprotein A-I","volume":"24","author":"Peng","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbalip.2012.11.002","article-title":"Cyclosporine A and PSC833 inhibit ABCA1 function via direct binding","volume":"1831","author":"Nagao","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_19","first-page":"107","article-title":"Antianxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model","volume":"19","author":"Roychoudhury","year":"1997","journal-title":"Methods Find. Exp. Clin. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2014.09.041","article-title":"Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: Possible implication of serotonergic system","volume":"744","author":"Gupta","year":"2014","journal-title":"Eur. J. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuropharm.2010.08.019","article-title":"Serotonergic modulation of extrapyramidal motor disorders in mice and rats: Role of striatal 5-HT3 and 5-HT6 receptors","volume":"60","author":"Ohno","year":"2011","journal-title":"Neuropharmacology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/17425255.2014.882317","article-title":"Ondansetron: A review of pharmacokinetics and clinical experience in postoperative nausea and vomiting","volume":"10","author":"Christofaki","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.2174\/138161206778522029","article-title":"5-HT3 receptors","volume":"12","author":"Thompson","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00023210-200519030-00004","article-title":"Selective Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting","volume":"19","author":"Gan","year":"2005","journal-title":"CNS Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.thromres.2012.06.003","article-title":"The anti-aggregation effects of ondansetron on platelets involve IP3 signaling and MAP kinase pathway, but not 5-HT3-dependent pathway","volume":"130","author":"Liu","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.atherosclerosis.2012.03.005","article-title":"PAPP-A negatively regulates ABCA1, ABCG1 and SR-B1 expression by inhibiting LXR\u03b1 through the IGF-I-mediated signaling pathway","volume":"222","author":"Tang","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1326-5-44","article-title":"Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid-\u03b2 peptides in the cerebral spinal fluid of rats","volume":"5","author":"Suon","year":"2010","journal-title":"Mol. Neurodegener."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000227054","article-title":"Mechanism of the anti-emetic activity of 5-HT3 receptor antagonists","volume":"49","author":"Tyers","year":"1992","journal-title":"Oncology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/BF02247730","article-title":"Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers","volume":"109","author":"Simpson","year":"1992","journal-title":"Psychopharmacology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.schres.2006.07.010","article-title":"Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A double-blind, randomized, placebo-controlled study","volume":"88","author":"Zhang","year":"2006","journal-title":"Schizophr. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1176\/appi.ajp.157.2.287","article-title":"Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia","volume":"157","author":"Sirota","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pbb.2015.07.004","article-title":"Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission","volume":"136","author":"Kurhe","year":"2015","journal-title":"Pharm. Biochem. Behav."},{"key":"ref_33","first-page":"43","article-title":"Differential effects of 5-HT3 receptor antagonist on lipid profile in spontaneously hypertensive rat and chromosome 8 congenic strain","volume":"2","author":"Krupkova","year":"2012","journal-title":"Neuro Endocrinol. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00019442-200203000-00013","article-title":"Ondansetron in the treatment of cognitive decline in Alzheimer dementia","volume":"10","author":"Dysken","year":"2002","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1093\/hmg\/ddx155","article-title":"APOE \u03b54\/\u03b54 diminishes neurotrophic function of human iPSC-derived astrocytes","volume":"26","author":"Zhao","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/brain\/awu046","article-title":"Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer\u2019s disease","volume":"137","author":"Shinohara","year":"2014","journal-title":"Brain"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00401-013-1086-9","article-title":"Brain regional correlation of amyloid-\u03b2 with synapses and apolipoprotein E in non-demented individuals: Potential mechanisms underlying regional vulnerability to amyloid-\u03b2 accumulation","volume":"125","author":"Shinohara","year":"2013","journal-title":"Acta Neuropathol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/6\/1488\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:40:23Z","timestamp":1760186423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/6\/1488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,25]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["ijms20061488"],"URL":"https:\/\/doi.org\/10.3390\/ijms20061488","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,25]]}}}